Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.
In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis.



Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele.



The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45-0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47-1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51-0.90; p = 0.008).



Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.
Department of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden. Magdalena.Bentmar_Holgersson@med.lu.se.
Magdalena
M
Bentmar Holgersson
Department of Urology, Skåne University Hospital, Malmö, Sweden.
Yasir
Y
Ruhayel
Department of Orthopedics and Clinical Sciences, Lund University, Malmö, Sweden.
Magnus
M
Karlsson
Department of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.
Aleksander
A
Giwercman
Department of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.|Department of Urology, Skåne University Hospital, Malmö, Sweden.
Anders
A
Bjartell
Departments of Internal Medicine and Clinical Nutrition and Geriatrics at the Sahlgrenska Academy, Center for Bone and Arthritis Research, Gothenburg University, Gothenburg, Sweden.
Claes
C
Ohlsson
Departments of Internal Medicine and Clinical Nutrition and Geriatrics at the Sahlgrenska Academy, Center for Bone and Arthritis Research, Gothenburg University, Gothenburg, Sweden.
Dan
D
Mellström
Department of Medical Sciences, University of Uppsala, Uppsala, Sweden.
Östen
Ö
Ljunggren
Department of Urology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Mohammad-Ali
MA
Haghsheno
Department of Urology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Jan-Erik
JE
Damber
Department of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.
Yvonne
Y
Lundberg Giwercman
D000328:Adult; D000368:Aged; D000483:Alleles; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D011944:Receptors, Androgen / Q000235:genetics*; D012307:Risk Factors; D013548:Sweden
D011944:Receptors, Androgen; D017430:Prostate-Specific Antigen
Androgen receptor; Genetic variants; Prostate cancer